Day: March 27, 2025

Sachem Capital Reports Full Year 2024 Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

– Company to Host Webcast and Conference Call – BRANFORD, Conn., March 27, 2025 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the year ended December 31, 2024. John Villano, CPA, Sachem Capital’s Chief Executive Officer commented, “We remain focused on effectively managing our loan portfolio and protecting our capital as we continue our efforts to navigate challenging financial and real estate markets. These efforts include managing our debt load and the associated carrying costs and selling non-performing loans, which should reduce the allowances for credit losses that have been a drag on earnings....

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. Docetaxel Plinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLC SEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 Financing SEED Therapeutics’ Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDAFLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced...

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2024. “We believe that our SERENITY program presents an exciting opportunity to address a substantial unmet medical need — the 23 million episodes...

Bitfarms Reports Fourth Quarter 2024 Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

– Revenue of $56 million, up 21% Y/Y –– Gross mining margin of 47%, down from 57% from Q4 2023 –– 18.6 EHuM up 186% from Q4 2023-– Current efficiency of 19w/TH a 45% improvement from Q4 2023--Total energy pipeline of ~1.4 GW, ~80% based in the U.S.--Completed acquisition of Stronghold Digital Mining & sale of Yguazu, Paraguay data center- This news release constitutes a “designated news release” for the purposes of the Company’s second amended and restated prospectus supplement dated December 17, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario and BROSSARD, Québec, March 27, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF), a global vertically integrated Bitcoin data center company, reported its financial results for the fourth quarter ended...

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2024. “We made important strides in 2024 as we became a public...

Winnebago Industries Reports Second Quarter Fiscal 2025 Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

— Improves Sequential Profitability, Driven by Margin Growth in All Segments — — Completes $100 Million High Yield Debt Tender, Enhancing Capital Efficiency Through Strategic Debt Reduction — — Barletta’s Share of U.S. Aluminum Pontoon Market Increases to 9.5%(1), up 140 Basis Points YoY — — Newmar Delivers its Fourth Straight Year of Increasing Market Share in Class A Diesel Segment(2) — EDEN PRAIRIE, Minn., March 27, 2025 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor lifestyle product manufacturer, today reported financial results for the fiscal 2025 second quarter ended March 1, 2025. Second Quarter Fiscal 2025 Financial SummaryNet revenues of $620.2 million Gross profit of $83.1 million, representing 13.4% gross margin Net loss of $0.4 million,...

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s diseaseAnticipate topline results in late 2026Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patients Cash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the...

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

Revenue in 2024 increased 342% year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong sales growth of olverembatinib Sales of olverembatinib in China in 2024 increased 52% year-over-year to US$33.0 million Completion of U.S. initial public offering on Nasdaq in January 2025, resulting in US$132.5 million in net proceeds Lisaftoclax accepted for New Drug Application (NDA) review with Priority Review designation in China Ten registrational trials in progress, including two cleared by FDA English conference call and webcast at 8:00 am EDT / 8:00 pm HKT on March 27, 2025 and Chinese (Mandarin) investor event with simultaneous conference call and webcast at 9:30 am HKT on March 28, 2025 / 9:30 pm EDT on March 27, 2025ROCKVILLE, Md. and SUZHOU, China, March 27, 2025 (GLOBE NEWSWIRE)...

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Written by Customer Service on March 27, 2025. Posted in Public Companies.

– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the positive results from our randomized, double-blind Phase 2 trial1, we are pleased to announce that the last participant has now completed all clinical evaluations in our open-label...

AKVA group ASA: Sale of shares in Abyss Group to Arcus Infrastructure Partners

Written by Customer Service on March 27, 2025. Posted in Public Companies.

Reference is made to the stock exchange notice on 12 March 2025 where AKVA group ASA (“AKVA”) announced the sale of its 21,55% ownership in Abyss Group AS to Arcus Infrastructure Partners LLP. The transaction was closed today. AKVA’s net proceeds from the sale is approx. MNOK 140 and will result in a positive accounting gain which will be recognized in Q1 2025. The proceeds from the transaction will be used for continued development of AKVA’s core business segments. Dated: 27 March 2025AKVA group ASA Web: www.akvagroup.com CONTACTS:Knut Nesse Chief Executive OfficerPhone: +47 51 77 85 00Mobile: +47 91 37 62 20E-mail: knesse@akvagroup.comRonny Meinkøhn Chief Financial OfficerPhone: +47 51 77 85 00Mobile: +47 98 20 67 76E-mail: rmeinkohn@akvagroup.com*** This information is considered to be inside...

Day: March 27, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals